AU2016212777B2 - Single domain antibodies targeting CD1d - Google Patents

Single domain antibodies targeting CD1d Download PDF

Info

Publication number
AU2016212777B2
AU2016212777B2 AU2016212777A AU2016212777A AU2016212777B2 AU 2016212777 B2 AU2016212777 B2 AU 2016212777B2 AU 2016212777 A AU2016212777 A AU 2016212777A AU 2016212777 A AU2016212777 A AU 2016212777A AU 2016212777 B2 AU2016212777 B2 AU 2016212777B2
Authority
AU
Australia
Prior art keywords
ser
gly
compound
cd1d
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU2016212777A
Other languages
English (en)
Other versions
AU2016212777A1 (en
Inventor
Renee Cornelia Gerarda De Bruin
Tanja Denise DE GRUIJL
Roland LAMERIS
Johannes Jelle VAN DER VLIET
Hendrik Marinus Willem VERHEUL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lava Therapeutics NV
Original Assignee
Lava Therapeutics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics NV filed Critical Lava Therapeutics NV
Publication of AU2016212777A1 publication Critical patent/AU2016212777A1/en
Application granted granted Critical
Publication of AU2016212777B2 publication Critical patent/AU2016212777B2/en
Priority to AU2022200922A priority Critical patent/AU2022200922A1/en
Assigned to LAVA Therapeutics N.V. reassignment LAVA Therapeutics N.V. Amend patent request/document other than specification (104) Assignors: Lava Therapeutics B.V.
Revoked legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
AU2016212777A 2015-01-27 2016-01-27 Single domain antibodies targeting CD1d Revoked AU2016212777B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200922A AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2014192 2015-01-27
NL2014192 2015-01-27
PCT/NL2016/050064 WO2016122320A1 (en) 2015-01-27 2016-01-27 Single domain antibodies targeting cd1d

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200922A Division AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Publications (2)

Publication Number Publication Date
AU2016212777A1 AU2016212777A1 (en) 2017-08-17
AU2016212777B2 true AU2016212777B2 (en) 2021-11-18

Family

ID=52630466

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016212777A Revoked AU2016212777B2 (en) 2015-01-27 2016-01-27 Single domain antibodies targeting CD1d
AU2022200922A Withdrawn AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200922A Withdrawn AU2022200922A1 (en) 2015-01-27 2022-02-11 Single domain antibodies targeting CD1d

Country Status (11)

Country Link
US (4) US10501541B2 (https=)
EP (1) EP3250608B1 (https=)
JP (2) JP6743051B2 (https=)
KR (2) KR20230132604A (https=)
CN (2) CN107531787B (https=)
AU (2) AU2016212777B2 (https=)
CA (1) CA2975078A1 (https=)
EA (1) EA201791691A1 (https=)
MX (1) MX386714B (https=)
SG (1) SG11201706128PA (https=)
WO (1) WO2016122320A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531787B (zh) 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
CA3121478A1 (en) * 2018-11-30 2020-06-04 Aleta Biotherapeutics Inc. Single domain antibodies against cll-1
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタｔ細胞活性化抗体の使用
CN114195891B (zh) * 2021-12-22 2023-05-12 北京世纪沃德生物科技有限公司 一种crp驼源单域抗体及其制备方法和应用
EP4285926A1 (en) * 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2024256586A1 (en) 2023-06-14 2024-12-19 LAVA Therapeutics N.V. Cd1d antibodies and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053021A1 (en) * 2011-10-14 2013-04-18 Cephalon Australia Pty Ltd ANTIBODIES TO CD1d

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
ES2201078T3 (es) 1993-06-21 2004-03-16 Brigham And Women's Hospital Metodos de aislar antigenos presentados por cd1, vacunas que comprenden antigenos presentados por cd1, y lineas celulares para usar en dichos metodos.
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
EP1198572A2 (en) 1999-08-02 2002-04-24 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
WO2001022816A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
AU2001259230A1 (en) 2000-04-28 2001-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions
DK2336187T3 (en) 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
EP1372668B1 (en) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
AU2003234443A1 (en) * 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
US7521543B2 (en) 2002-10-23 2009-04-21 Ludwig Institute For Cancer Research A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
WO2005046711A2 (en) 2003-11-07 2005-05-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
EP1778836B1 (en) 2004-08-19 2010-08-04 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
CA2584971C (en) 2004-11-02 2013-08-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
US8338173B2 (en) 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
EP1990410B1 (en) * 2006-02-22 2020-01-08 Riken IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
EP1878440A1 (en) 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
US8012484B2 (en) 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
WO2010130830A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
AU2013201422B2 (en) 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2831109B1 (en) 2012-03-28 2017-12-06 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014210522A1 (en) 2013-06-28 2014-12-31 The Scripps Research Institute Nkt cell ligands and methods of use
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
EP3129404B1 (en) 2014-04-10 2026-01-28 LAVA Therapeutics N.V. Immunoglobulins binding human vgamma9vdelta2 t cell receptors
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
KR20170021354A (ko) 2014-07-02 2017-02-27 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) CD1d 제한된 감마/델타 T 세포 림프종을 진단 및 치료하는 방법
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
CN107531787B (zh) 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CN104829730A (zh) 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
CN109195992A (zh) 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用
CA3032304A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
RU2020135920A (ru) 2018-04-05 2022-05-05 Новартис Аг Триспецифические связывающие молекулы против форм рака и пути их применения
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP3965818A4 (en) 2019-05-08 2023-05-31 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY
US20220290101A1 (en) 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
CA3145523A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
IL296358A (en) 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053021A1 (en) * 2011-10-14 2013-04-18 Cephalon Australia Pty Ltd ANTIBODIES TO CD1d

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BROWN, M. et al., "Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2", The Journal of Immunology. 1996, Vol. 156, No. 9, pages 3285-3291 *
RUDIKOFF, S. et al., "Single amino acid substitution altering antigen-binding specificity", PNAS. 1982, Vol. 79, pages 1979-1983 *
SIONTOROU, C.G. et al., "Nanobodies as novel agents for disease diagnosis and therapy", International Journal of Nanomedicine, 2013. Vol. 8, pages 4215-4227 *
WINKLER, K. et al., "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody", The Journal of Immunology. 2000, Vol. 165, No. 8, pages 4505-4514 *

Also Published As

Publication number Publication date
CA2975078A1 (en) 2016-08-04
JP7165701B2 (ja) 2022-11-04
MX386714B (es) 2025-03-11
AU2016212777A1 (en) 2017-08-17
KR20170128254A (ko) 2017-11-22
EA201791691A1 (ru) 2018-01-31
US10501541B2 (en) 2019-12-10
US20240067726A1 (en) 2024-02-29
US12110328B2 (en) 2024-10-08
WO2016122320A1 (en) 2016-08-04
KR102574729B1 (ko) 2023-09-04
US20240425592A1 (en) 2024-12-26
JP6743051B2 (ja) 2020-08-19
CN107531787A (zh) 2018-01-02
SG11201706128PA (en) 2017-08-30
US20180142020A1 (en) 2018-05-24
HK1247937A1 (en) 2018-10-05
AU2022200922A1 (en) 2022-03-03
EP3250608B1 (en) 2024-08-21
EP3250608A1 (en) 2017-12-06
JP2018508229A (ja) 2018-03-29
MX2017009680A (es) 2018-04-13
CN107531787B (zh) 2022-01-18
US20200115450A1 (en) 2020-04-16
JP2020172550A (ja) 2020-10-22
KR20230132604A (ko) 2023-09-15
CN114504645A (zh) 2022-05-17
US11591394B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
US12110328B2 (en) Single domain antibodies targeting CD1d
US20250026840A1 (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
EP3858856A1 (en) Anti-b7-h3 monoclonal antibody and use thereof in cell therapy
EP3708582A1 (en) 4-1bb antibody and preparation method and use thereof
TW202546009A (zh) 抗hk2嵌合抗原受體(car)
CN116731169B (zh) 一种分拣蛋白1特异性的纳米抗体及其应用
CN104284903A (zh) 抗磷脂酶d4抗体
TWI800824B (zh) 一種抗cd19抗體的抗體及其製備和應用
CN118103071A (zh) Herv-k抗体治疗剂
EP4397685A1 (en) Anti-cd3 humanized antibody
EP4506368A1 (en) Bispecific antibody to human tim-3 and human cd39, and applications thereof
US20250333515A1 (en) Binding agents and methods of use thereof
WO2023001155A1 (zh) 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
CN108610422A (zh) 抑制pd-1/pd-l1信号通路的结合分子
JP2024517985A (ja) 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー
HK1247937B (en) Single domain antibodies targeting cd1d
EA042112B1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
CN118488961A (zh) Herv-k抗体、细胞、疫苗及药物治疗剂
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
WO2023177821A2 (en) Binding domains and methods of use thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: LAVA THERAPEUTICS N.V.

Free format text: FORMER NAME(S): LAVA THERAPEUTICS B.V.

FGA Letters patent sealed or granted (standard patent)
MAK Offer to surrender letters patent
MAL Surrender and revocation of letters patent

Effective date: 20250116